IM and SC Injections in Burns: Affected Area Only
The statement refers to avoiding IM and subcutaneous injections specifically in burned tissue areas, not as a blanket contraindication throughout the entire body in burn patients. However, the systemic pharmacokinetic alterations in burn patients mean that even injections in non-burned areas may have unpredictable absorption patterns, particularly during the acute phase.
Understanding the Context
The concern about altered absorption operates on two distinct levels:
Local (Burned Tissue) Considerations
- Direct injection into burned skin is contraindicated due to:
- Destroyed vascular architecture preventing normal drug absorption
- Risk of introducing infection into compromised tissue
- Unpredictable and likely minimal systemic absorption from damaged tissue
- Potential for drug accumulation in necrotic tissue
Systemic Pharmacokinetic Alterations
Burn injury creates a biphasic response that affects drug handling throughout the body 1, 2:
Phase 1 (First 48 hours - Burn Shock):
- Hypovolemia and edema formation
- Reduced cardiac output and tissue perfusion
- Slower drug distribution and absorption from IM/SC sites even in non-burned areas
- Lower glomerular filtration rate
- Hypoalbuminemia affecting protein binding
Phase 2 (Beyond 48 hours - Hyperdynamic State):
- Increased cardiac output and organ blood flow
- Enhanced renal and hepatic clearance
- Potentially faster but still unpredictable absorption
- Altered protein binding (increased α1-acid glycoprotein, decreased albumin)
Practical Clinical Implications
For medication administration in burn patients:
- Avoid IM/SC injections in burned tissue at all times - this is absolute
- Prefer intravenous route for systemic medications during acute burn management, as it bypasses absorption variability and allows for titration 3
- If IM/SC routes must be used in non-burned areas:
Special Considerations
The guideline evidence emphasizes intravenous administration for acute burn care 3, particularly noting that analgesics and other critical medications should be "titrated intravenously" rather than given via other routes during the acute phase.
Common pitfall: Assuming that IM/SC injections in non-burned areas will behave normally in major burn patients (>15-20% TBSA). The systemic inflammatory response and fluid shifts affect drug distribution throughout the body, not just at the burn site 1, 2, 4.
Bottom line: Your textbook's statement primarily warns against injecting directly into burned tissue, but the underlying pharmacokinetic science reveals that systemic alterations make IM/SC routes problematic throughout the body in major burns, making IV the preferred route for acute management.